Darapladib in conjunction with statin drugs may reduce risk of heart attacks and stroke
Researchers have indicated that an enzyme found in coronary plaques may be responsible for significant number of cardiac patients suffering from heart attacks and stroke, despite the widespread use of cholesterol-lowering drugs. The enzyme makes plaque more vulnerable to rupture and block blood flow. According to new research, the drug darapladib, taken in adjunct to the treatment of statin drugs, may offer a way to fight that risk as it safely and effectively lowers the activity of the Lp-PLA2 enzyme.
-
Drugs to Prevent Heart Disease Increase Risk of Kidney Failure
Telmisartan helps in reducing cardiovascular risk
Study: Statins lower death risk after artery surgery
FDA Looking Into Heart-Related Death Risk of Benicar
Acorda Therapeutics Announces Receipt Of NIH Grant For Development Of GGF2 In Heart Failure
Paul on 16 May 2008 at 6:17 pm #
Sounds good, but without outcomes data, this means nothing. So what if it lowers a marker that has been shown to be correlated with high risk (but not independent of LDL). Until someone can show that lowering Lp-PLA2 has a positive effect, it has not utility.